Introduction: Rheumatoid arthritis (RA) is a common disease characterized by chronic inflammation and erosion of the joints associated with functional impairment. The main therapy for symptomatic relief in RA is based on NSAIDs as the first group of drugs utilized all over the world; however they are frequently associated with a fair degree of side effects. Methods: We conducted a randomized double blind, placebo controlled trial to assess the efficacy and safety of a polyherbal drug Qurs-e-Mafasil in patients of active rheumatoid arthritis. Total 125 patients completed the study up to 12 weeks; they received either Qurs-e-Mafasil or Placebo in the dose of two tablets thrice daily. Efficacy and safety assessment was done at base line and then at every 4-week__ampersandsign#39;s treatment up to 12 weeks. Results: In Qurs-e-Mafasil treatment group marked improvement was achieved in tender joint count (p =0. 002), swollen joint count (P=0.001) and pain intensity score (P=0.0001). This improvement was significantly greater as compared to Placebo group. There was no significant difference between treatment groups regarding the number of patients that reached ACR20 improvement criteria in the assessments after 12 weeks of treatment, but improvement in quality of life is significantly greater in Qurs-e-Mafasil group than in placebo group. Conclusion: Qurs-e- Mafasil exerted significant effect in pain relief, reduction in tender and swollen Join count and functional improvement without producing adverse effects.